Ionis Pharmaceuticals (IONS) Reports Strong 1Q, Eplontersen PN Data Soon - BMO Capital

May 6, 2022 6:54 AM EDT Send to a Friend
BMO Capital analyst Do Kim reiterated an Outperform rating and $70.00 price target on Ionis Pharmaceuticals (NASDAQ: IONS) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login